Please login to the form below

Tyverb

This page shows the latest Tyverb news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s first-in-class breast cancer therapy wins EU licence

A number of metastatic breast cancer treatments have been rejected by the UK cost-effectiveness watchdog over the last few years, including GlaxoSmithKline's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab),

Latest news

Oncology directions

For advanced breast cancer, Novartis's newly acquired breast cancer drug Tyverb (lapatinib) scores five, but there are four drugs that score three or less, including Eisai's breast cancer medicine
Novartis and GSK complete oncology and vaccines swap

Details of the asset swap were first revealed last April. Novartis claims ownership of several marketed products - including kidney cancer therapy Votrient (pazopanib) and Tyverb (lapatinib) for breast cancer - and also
England's Cancer Drugs Fund: Fixing a broken system

eribulin), GSK's Tyverb (lapatinib) and Novartis' Afinitor (everolimus)), were to be de-listed. ... GlaxoSmithKline's Tyverb (lapatinib):. treatment of advanced breast cancer. GlaxoSmithKline's Arzerra (ofatumumab):.
Pharma condemns Cancer Drugs Fund cuts

GSK. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib). Breast cancer. Votrient (pazopanib).
NHS names drugs to be re-evaluated for Cancer Drugs Fund

Chronic lymphocytic leukaemia. GlaxoSmithKline. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib).

More from news
Approximately 3 fully matching, plus 35 partially matching documents found.

Latest appointments

GSK's oncology president joins NuCana board

During this time he has worked on major cancer products, such as Tykerb/Tyverb and Mekinist.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Associate Medical Director: Highly Competitive

Senior Account Executive – Medical Communications: Salary TBC

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Manager, Healthcare Advertising: Salary TBC

Scientific Director: Highly Competitive Salary &Benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Experienced Editor, London, Medical Communications: Competitive package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Scientific Team Lead: Competitive Salary

Consultant Health Economics - London / Oxford: Negotiable

Editorial Director – Medical Education: Neg

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Account Director – Global Healthcare PR: Salary TBC

Account Director: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Director Healthcare PR Communications: Salary TBC

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Senior Systematic Review Analyst - Oxford: Negotiable

Director – Head of Public Affairs: Neg

Associate Medical Director: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe: Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...